Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

biOasis Technologies Ord Shs V.BTI.H

Alternate Symbol(s):  BIOAF

Healthcare Biotechnology
Bioasis Technologies Inc. is a Canada-based biopharmaceutical company focused on research and development of technologies and products intended for the treatment of patients with nervous system, including central nervous system, diseases and disorders. The Company is engaged in the development of its xB 3 platform, which is a peptide-based technology, for the transport of therapeutic agents, in particular biological products, across the blood-brain barrier (BBB). It is focused on both orphan drug indications, including brain cancers, and rare genetic neurodegenerative diseases and neuroinflammatory conditions. The Company is also focused on its Epidermal Growth Factor (EGF) platform for treating rare and orphan neurodegenerative and neuroinflammatory disorders. EGF is a protein that stimulates cell growth and differentiation, notably for myelin producing cells. Its development programs include xB3-001: Brain Metastases, xB3-002: Glioblastoma and xB3-007: Neurodegenerative Disease.


TSXV:BTI.H - Post by User

biOasis Technologies Ord Shs > Grow up and move on please...
<< Previous
 Bullboard Posts
Next >>
User Avatar Image
(57)
•••
Comment by Comonreally42on Nov 17, 2022 12:59am
133 Views
Post# 35105771

RE:RE:RE:RE:RE:RE:RE:RE:RE:Grow up and move on please...

RE:RE:RE:RE:RE:RE:RE:RE:RE:Grow up and move on please...xB3 ( stupid name) has little to no commercial value. After 14 years the stock sits .145 cents and not one Pharma has steped up in a material way. The runway is short, its a heavy plane with a payload that is questionable and all the pilots in the world likely couldnt of got this off the ground. Maybe start pulling stats on penny stocks that just delist, close their doors and drift off into the ether like Hunter S Thompson. It happens, more than you know. You are emotional about this, professionally, financially, you may even pray about it. None of those are good signs. You might want to zoom out and "take stock" of your path, chalk it up to experience and apply it to the next one, but you are clinging to this one like its the only thing that matters to you and it shows and why so many people rip you.
<< Previous
 Bullboard Posts
Next >>
Dealroom for high-potential pre-IPO opportunities